Overview
Zimmer Biomet Holdings, Inc. is a global medical technology company focused on orthopedics and products for conditions and injuries affecting bones, joints and supporting tissues. Its portfolio includes hip and knee reconstruction, sports medicine, biologics, extremities and trauma, craniomaxillofacial and thoracic products, and digital and robotic technologies such as ROSA.[1][2][3][4]
The company’s stated mission is “to alleviate pain and improve the quality of life for people around the world.” It reports approximately 17,000 team members, more than 30 global offices, and products used in over 100 countries.[5] Zimmer Biomet reported FY2025 net sales of $8.232 billion, with operations reported across the Americas, EMEA and Asia Pacific.[6] [1][2][3][4][6][5]
Products & services
Zimmer Biomet’s products include joint-replacement implants for knees and hips, sports-medicine and biologic products, extremity and trauma devices, craniomaxillofacial and thoracic products, bone cement, surgical products, and robotic and digital technologies. Its knee portfolio includes Persona®, NexGen®, Vanguard® and Oxford® partial-knee implants for primary, revision and partial procedures. Persona offers cemented and cementless options and different bearing configurations. Hip products include the Taperloc®, Avenir Complete®, Z1®, Arcos® and G7® systems; these support primary and revision replacement, with fixation options including cement and press-fit designs.[2][7][8][9][10]
The ROSA® robotic systems assist with knee, hip and shoulder procedures: ROSA Knee supports bone resections and intraoperative soft-tissue assessment; ROSA Hip provides robotic guidance for acetabular orientation and leg-length assessment; and ROSA Shoulder supports glenoid and humeral preparation in anatomic and reverse shoulder procedures. Other named products include the JuggerKnot® soft anchor for soft-tissue fixation, Gel-One® cross-linked hyaluronate, Gorilla® ankle-fracture plates, the Comprehensive® shoulder system, Natural Nail® and SternaLock® systems. The A.L.P.S. hand-fracture system includes contourable plates and locking, non-locking and multidirectional screw options; ToggleLoc® with ZipLoop® is an ACL fixation device with an adjustable loop.[8][9][3][11][12][13][14][15]
Digital and service offerings include the ZBEdge® platform, which combines surgical technologies and data intended to support care decisions, and mymobility®, a care-management platform offering patient education, remote monitoring and progress information for care teams. The company also describes surgical solutions for healthcare institutions and education for healthcare professionals. In 2025, sports medicine, biologics, foot and ankle, upper extremities, trauma, and craniomaxillofacial and thoracic products accounted respectively for 12%, 5%, 12%, 30%, 20% and 21% of S.E.T. net sales; these percentages are of that category, not total company revenue.[16][3][17][18] [2][7][8][9][3][16][10][11][12][13][14][15][17][18][10][11][12][13][14][15][17][18]
Geographic presence
Zimmer Biomet reports sales across three commercial regions: the Americas, comprising the U.S. and other North, Central and South American markets; EMEA, covering Europe, the Middle East and Africa; and Asia Pacific. Its named markets include France, Germany, Italy, Spain and the UK in EMEA, and Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong and Malaysia in Asia Pacific. The company describes its products as available in more than 100 countries.[19][20][21][5]
For 2025, net sales were $5,144.6 million in the Americas (approximately 62.5% of total), $1,828.8 million in EMEA (22.2%) and $1,258.1 million in Asia Pacific (15.3%). The U.S. represented about 95% of Americas sales; France, Germany, Italy, Spain and the UK together represented about half of EMEA sales; and Japan represented about half of Asia Pacific sales.[6][22][20][21]
Warsaw, Indiana, is the company’s corporate headquarters and a major center for manufacturing and other operations. Zimmer Biomet has approximately 300 facilities worldwide, around half in the U.S., and approximately 25 manufacturing locations in the U.S. and internationally; its most significant manufacturing locations outside the U.S. are in Switzerland, Ireland and China. The company also identifies R&D facilities in Warsaw, Montreal, Denver, Jacksonville, Austin, Zug and Beijing. In September 2026, it announced a global headquarters move within Warsaw to 1800 W. Center Street, which is listed as its corporate headquarters on its contact page.[23][24][25][26][27] [19][20][21][5][6][6][6][22][23][24][25][26][27][26][27][5]
Business segments
Zimmer Biomet reports three operating segments, organized geographically rather than by product: Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific [28]. Based on FY2025 net sales of $8,231.5 million, the Americas contributed approximately 62.5% ($5,144.6 million) [6], EMEA 22.2% ($1,828.8 million) [6], and Asia Pacific 15.3% ($1,258.1 million) [6]. These percentages are calculated from each segment’s reported net sales and the company total.
The Americas segment covers markets across North, Central and South America, with the United States accounting for most of its sales [22]. EMEA includes European markets as well as the Middle East and Africa [20]. Asia Pacific includes markets such as Japan, China, Australia, New Zealand, Korea and India [21]. Across these regions, the company’s portfolio includes orthopedic reconstruction, sports medicine, biologics, extremities and trauma, CMFT, bone cement, surgical products, and digital and robotic technologies; the segment disclosures do not assign these product categories to individual regions [2][3]. [28][6][6][6][6][22][20][21][2][3]
Company history
Zimmer Biomet’s history traces to Zimmer Manufacturing Company, founded in Warsaw, Indiana, in 1927; Biomet, a separate predecessor founded by former Zimmer employees, was established in 1977.[29][30][31] Zimmer became an independent public company in 2001 through a spin-off from its former parent, then expanded through its 2003 acquisition of Centerpulse.[29][32][33]
In 2013, Zimmer introduced its Persona personalized knee system.[34] The present combined company was formed in 2015, when Zimmer acquired Biomet’s parent and changed its name from Zimmer Holdings to Zimmer Biomet Holdings.[29][35] In 2016, it acquired LDR Holding, expanding its spine business, and Medtech, whose ROSA robotics platform became part of Zimmer Biomet’s portfolio.[36][37]
In 2022, Zimmer Biomet spun off its spine and dental businesses as ZimVie.[38] It acquired Embody in 2023, adding soft-tissue healing technologies, and in 2024 announced the first robotic-assisted shoulder replacement using ROSA Shoulder.[39][40][41] In 2025, it completed the acquisition of Paragon 28, a company focused on foot-and-ankle medical devices.[42][43][44] [29][42][43][30][31][32][33][34][35][36][37][38][39][40][41][44]
Sources
- ZIMMER BIOMET HOLDINGS, INC. — Full financial report (2025 Y)
- www.zimmerbiomet.com[5]
- www.zimmerbiomet.com[10]
- www.zimmerbiomet.com[11]
- www.zimmerbiomet.com[12]
- www.zimmerbiomet.com[13]
- www.zimmerbiomet.com[14]
- www.zimmerbiomet.com[15]
- www.zimmerbiomet.com[17]
- www.zimmerbiomet.com[18]
- hub.zimmerbiomet.com[26]
- www.zimmerbiomet.com[27]
- hub.zimmerbiomet.com[30]
- investor.zimmerbiomet.com[31]
- investor.zimmerbiomet.com[32]
- investor.zimmerbiomet.com[33]
- investor.zimmerbiomet.com[34]
- investor.zimmerbiomet.com[35]
- investor.zimmerbiomet.com[36]
- investor.zimmerbiomet.com[37]
- investor.zimmerbiomet.com[38]
- investor.zimmerbiomet.com[39]
- investor.zimmerbiomet.com[40]
- investor.zimmerbiomet.com[41]
- investor.zimmerbiomet.com[44]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore ZIMMER BIOMET HOLDINGS, INC. in Finbar ↗